Trials / Completed
CompletedNCT00407927
A Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis
A Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Safety, Efficacy, and Tolerability Study of Two Doses of Epinastine Nasal Spray (0.05% and 0.1%) vs. Placebo in Subjects With Seasonal Allergic Rhinitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 571 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- —
Summary
The purpose of this trial is to determine the safety, efficacy and tolerability of two doses of the study drug compared to placebo for the treatment of subjects with seasonal allergic rhinitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Epinastine Nasal Spray |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2007-03-01
- Completion
- 2007-03-01
- First posted
- 2006-12-05
- Last updated
- 2015-10-12
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00407927. Inclusion in this directory is not an endorsement.